Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Daiichi Sankyo And AstraZeneca's Supplemental Biologics License Application For ENHERTU® Accepted And Granted Priority Review By The FDA For Patients With Metastatic HER2 Positive Solid Tumors

Author: Benzinga Newsdesk | January 29, 2024 03:19am
  • Application based on results from DESTINY-PanTumor02 trial and supported by additional ENHERTU data
  • Submission to be reviewed under FDA Real Time Oncology Review and Project Orbis
  • If approved, Daiichi Sankyo and AstraZeneca's ENHERTU will potentially be the first HER2 directed treatment and antibody drug conjugate to receive a tumor agnostic indication

Posted In: AZN DSNKY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)
CORE Finalist